Vertaling van "significant need for developing " (Nederlands → Frans) :

There is still a significant need for developing better medicines in a number of domains.
There is still a significant need for developing better medicines in a number of domains.

Vaccines and Diagnostics Operating income rose to USD 583 million from USD 26 million in the 2008 period, while core operating income of USD 653 million in the 2009 quarter reflected the recognition of exceptional contributions from sales of A (H1N1) pandemic flu vaccines during the period that were made possible by significant investments in development and manufacturing earlier in the year.
Vaccins et Diagnostic Le résultat opérationnel a bondi à USD 583 millions contre USD 26 millions au quatrième trimestre 2008. Le résultat opérationnel «core» d’USD 653 millions a comptabilisé des contributions exceptionnelles provenant de ventes de vaccins contre la pandémie de grippe A(H1N1) rendues possibles par des investissements importants effectués en début d’année dans le développement et la fabrication de ces vaccins.

For more than 25 years, the Novartis Foundation for Sustainable Development has made significant contributions to the health of people in the developing world.
Depuis plus de 25 ans, la Fondation Novartis pour un développement durable contribue de manière significative à améliorer la santé des populations dans les pays en

To raise Belgium’s profile even further in the European context, regulatory and scientific expertise needs to carry on being developed, and the quality of the services delivered needs to be monitored and improved continuously.
To raise Belgium’s profile even further in the European context, regulatory and scientific expertise needs to carry on being developed, and the quality of the services delivered needs to be monitored and improved continuously.

2010: Delivering on strategic priorities Novartis expects 2010 to be a year of significant progress in implementing its strategy to meet the growing needs of patients and aging societies worldwide through its healthcare portfolio.
En 2010, créer de la valeur grâce aux priorités stratégiques Novartis prévoit que 2010 verra des progrès sensibles dans la mise en œuvre de sa stratégie consistant à satisfaire les besoins croissants des malades et des populations vieillissantes du monde entier grâce à son portefeuille de soins de santé.

These priorities are: (1) extending our lead in innovation by focusing on diseases with significant unmet need and delivering positive patient outcomes; (2) accelerating growth across all divisions through tailored commercial models that leverage our broad portfolio and expansion in emerging markets; and (3) driving productivity across our business to continue improving margins and reinvesting for future growth.
Ces priorités sont: 1) augmenter notre avance dans l’innovation en nous concentrant sur des besoins non satisfaits des soins de santé et sur l'efficacité des médicaments pour les patients, 2) accélérer notre croissance dans toutes les divisions, par le biais de modèles commerciaux taillés sur mesure qui tirent le meilleur parti de notre vaste portefeuille, et nous étendre dans les marchés émergents et 3) accroître la productivité dans toutes nos activités afin de continuer d’améliorer nos marges et de réinvestir dans notre croissance future.

Members of the Transparency Committee have a significant responsibility: not only because they’ve accepted the mission to oversee good governance in the Agency, but also, primarily, because they have signed up to working on the development of an effective Agency.
Members of the Transparency Committee have a significant responsibility: not only because they’ve accepted the mission to oversee good governance in the Agency, but also, primarily, because they have signed up to working on the development of an effective Agency.

The Belgian Federal Agency for Medicines and Health Products, although it is still undergoing significant developments, will seize every opportunity to ensure higher levels of quality and improve its performance.
The Belgian Federal Agency for Medicines and Health Products, although it is still undergoing significant developments, will seize every opportunity to ensure higher levels of quality and improve its performance.

The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.
The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.

Recognition by the relevant parties at national level and by the other competent authorities at European level for early phase development has without a doubt been a significant achievement for the R&D department and the FAMHP.
Recognition by the relevant parties at national level and by the other competent authorities at European level for early phase development has without a doubt been a significant achievement for the R&D department and the FAMHP.